FDMT250117C15000
- 0.05
- 0.000.00%
4D Molecular Therapeutics Newsroom
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $46
Express News | 4D Molecular Therapeutics Inc : BofA Global Research Cuts Price Objective to $46 From $79
Express News | 4Dmt Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in Iovs
We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth
4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now
4D Molecular Initiated by Morgan Stanley at Underweight
4D Molecular Therapeutics Analyst Ratings
Morgan Stanley Initiates 4D Molecular Therapeutics(FDMT.US) With Sell Rating, Announces Target Price $8
4D Molecular Therapeutics' Positive Q3 and Strategic Advances
Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $39
4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital
Analyst Expectations For 4D Molecular Therapeutics's Future
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating
H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36
Barclays Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $45
Barclays Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
Express News | 4D Molecular Therapeutics Inc : RBC Cuts Target Price to $39 From $40
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates